Advice
in the absence of a submission from the holder of the marketing authorisation
sufentanil citrate (Zalviso ®) is not recommended for use within NHS Scotland.
Indication under review: Management of acute moderate to severe post-operative pain in adult patients.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice68KB (PDF)
Medicine details
- Medicine name:
- sufentanil citrate (Zalviso)
- SMC ID:
- 1270/17
- Indication:
- management of acute moderate to severe post-operative pain in adult patients.
- Pharmaceutical company
- Grünenthal Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 August 2017